Anti-Factor Bb Antibodies Inhibit Complement Dysregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Age-related Macular Degeneration (AMD) is characterized by deregulation of the complement system, leading to excessive activation of the complement cascade, which causes inflammatory responses and tissue damage, resulting in progressive vision loss, and existing treatments are inadequate in addressing this underlying complement dysregulation.
Innovation Solution
Development of anti-Factor Bb antibodies that bind with high affinity to complement Factor Bb, inhibiting its activity and blocking the formation of the membrane attack complex, thereby modulating the complement pathway to prevent and treat AMD and other complement-associated eye conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for AMD, then general symptom management is provided, but the underlying complement dysregulation is not addressed
Solution Approach 1:
The patent extracts and targets the specific pathogenic element (Factor Bb) from the complement system. By developing antibodies that specifically bind to Factor Bb, the invention removes this particular component's harmful activity while leaving the rest of the complement system intact, thereby addressing the root cause of AMD rather than just managing symptoms
Solution Approach 2:
The patent introduces anti-Factor Bb antibodies as intermediary molecules that mediate between the harmful Factor Bb and the desired therapeutic outcome. These antibodies serve as a bridge that blocks Factor Bb's interaction with C3b and prevents MAC formation, thereby transmitting the therapeutic effect of complement inhibition
2Reliability
If complement activation is allowed to proceed, then immune defense and tissue homeostasis are maintained, but excessive activation causes inflammatory responses and tissue damage
Solution Approach 1:
The patent applies local quality control by specifically targeting Factor Bb within the complement system rather than inhibiting the entire complement cascade. The anti-Factor Bb antibodies selectively modulate the alternative pathway while preserving other complement functions, achieving localized inhibition where needed without compromising overall immune defense
Solution Approach 2:
The patent changes the activation parameter of the complement system by introducing antibodies that bind to Factor Bb and prevent its catalytic activity. This parameter change shifts the system from uncontrolled activation to regulated inhibition, reducing inflammatory damage while maintaining necessary immune functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-Factor Bb antibodies effectively inhibit complement-dependent hemolysis and MAC formation, providing a targeted approach to manage AMD by reducing inflammatory damage and slowing disease progression.
Implementation Method 1
anti-Factor Bb antibodies that bind with high affinity to complement Factor Bb
Data Source
AI summary
The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.